Edwards Lifesciences Pre-Tax Income 2010-2025 | EW
Edwards Lifesciences annual/quarterly pre-tax income history and growth rate from 2010 to 2025. Pre-tax income can be defined as company's earnings or loss before taxes on income have been accounted for.
- Edwards Lifesciences pre-tax income for the quarter ending March 31, 2025 was $0.434B, a 5.98% increase year-over-year.
- Edwards Lifesciences pre-tax income for the twelve months ending March 31, 2025 was $1.573B, a 13.69% increase year-over-year.
- Edwards Lifesciences annual pre-tax income for 2024 was $1.548B, a 12.8% increase from 2023.
- Edwards Lifesciences annual pre-tax income for 2023 was $1.372B, a 9.68% decline from 2022.
- Edwards Lifesciences annual pre-tax income for 2022 was $1.52B, a 10.72% decline from 2021.
| Edwards Lifesciences Annual Pre-Tax Income (Millions of US $) |
|
|---|---|
| 2024 | $1,548 |
| 2023 | $1,372 |
| 2022 | $1,520 |
| 2021 | $1,702 |
| 2020 | $917 |
| 2019 | $1,167 |
| 2018 | $761 |
| 2017 | $1,035 |
| 2016 | $738 |
| 2015 | $622 |
| 2014 | $1,144 |
| 2013 | $511 |
| 2012 | $388 |
| 2011 | $284 |
| 2010 | $268 |
| 2009 | $304 |
| Edwards Lifesciences Quarterly Pre-Tax Income (Millions of US $) |
|
|---|---|
| 2025-03-31 | $434 |
| 2024-12-31 | $349 |
| 2024-09-30 | $403 |
| 2024-06-30 | $387 |
| 2024-03-31 | $409 |
| 2023-12-31 | $311 |
| 2023-09-30 | $388 |
| 2023-06-30 | $275 |
| 2023-03-31 | $399 |
| 2022-12-31 | $211 |
| 2022-09-30 | $407 |
| 2022-06-30 | $465 |
| 2022-03-31 | $436 |
| 2021-12-31 | $376 |
| 2021-09-30 | $391 |
| 2021-06-30 | $546 |
| 2021-03-31 | $389 |
| 2020-12-31 | $356 |
| 2020-09-30 | $364 |
| 2020-06-30 | $-168 |
| 2020-03-31 | $365 |
| 2019-12-31 | $316 |
| 2019-09-30 | $302 |
| 2019-06-30 | $271 |
| 2019-03-31 | $278 |
| 2018-12-31 | $-2 |
| 2018-09-30 | $249 |
| 2018-06-30 | $251 |
| 2018-03-31 | $264 |
| 2017-12-31 | $324 |
| 2017-09-30 | $212 |
| 2017-06-30 | $206 |
| 2017-03-31 | $294 |
| 2016-12-31 | $200 |
| 2016-09-30 | $185 |
| 2016-06-30 | $169 |
| 2016-03-31 | $183 |
| 2015-12-31 | $167 |
| 2015-09-30 | $151 |
| 2015-06-30 | $142 |
| 2015-03-31 | $163 |
| 2014-12-31 | $133 |
| 2014-09-30 | $121 |
| 2014-06-30 | $813 |
| 2014-03-31 | $77 |
| 2013-12-31 | $100 |
| 2013-09-30 | $100 |
| 2013-06-30 | $121 |
| 2013-03-31 | $191 |
| 2012-12-31 | $119 |
| 2012-09-30 | $93 |
| 2012-06-30 | $90 |
| 2012-03-31 | $86 |
| 2011-12-31 | $69 |
| 2011-09-30 | $58 |
| 2011-06-30 | $73 |
| 2011-03-31 | $85 |
| 2010-12-31 | $70 |
| 2010-09-30 | $66 |
| 2010-06-30 | $66 |
| 2010-03-31 | $66 |
| 2009-12-31 | $62 |
| 2009-09-30 | $94 |
| 2009-06-30 | $63 |
| 2009-03-31 | $85 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | MED INSTRUMENTS | $44.196B | $5.440B |
| Edwards Lifesciences Corporation deals in products and technologies aimed at treating advanced cardiovascular diseases, especially structural heart disease in critically ill patients. The company is the world's leading manufacturer of tissue heart valves and repair products used to replace or repair a patient's diseased or defective heart valve. Edwards is also a leading player in hemodynamic monitoring systems used to measure a patient's cardiovascular function in the hospital setting. The company's products and technologies are categorized into four main areas: Transcatheter Aortic Valve Replacement (TAVR), Transcatheter Mitral and Tricuspid Therapies (TMTT), Surgical Structural Heart, and Critical Care. | |||